OCT4
- 1 October 2004
- journal article
- research article
- Published by Wolters Kluwer Health in The American Journal of Surgical Pathology
- Vol. 28 (10) , 1341-1346
- https://doi.org/10.1097/01.pas.0000135528.03942.1f
Abstract
The prognosis and therapy for dysgerminomas are different from those of other ovarian tumor types, making accurate diagnosis imperative for patient care. OCT4 (POU5F1) is a transcription factor involved in the regulation of pluripotency during embryonic development. It can be detected in both pluripotent cells and other early germ cells. This study examines the expression of OCT4 in both dysgerminoma and nondysgerminomatous neoplasms involving the ovary. Formalin-fixed, paraffin-embedded cell blocks of 33 cases of dysgerminoma including 2 cases of gonadoblastoma associated with dysgerminoma and 3 cases of metastatic dysgerminoma, and 111 cases of nondysgerminomatous neoplasms involving the ovary were stained using the antibody against OCT4. All cases of dysgerminomas and gonadoblastomas were positive for OCT4 with strong nuclear staining. More than 90% of dysgerminoma cells in each case showed diffuse strong nuclear staining. In addition, 3 metastatic dysgerminomas also showed uniform strong nuclear staining. All nondysgerminomatous tumors (mature teratoma, 14; yolk sac tumor, 4; Sertoli-Leydig cell tumor, 15; granulosa cell tumor, 22; Brenner tumor, 3; carcinoid tumor, 4; struma ovarii, 2; fibroma, 5; thecoma, 1; serous adenocarcinoma, 5; endometrioid adenocarcinoma, 4; small cell carcinoma, 6; stromal sarcoma, 1; malignant lymphoma, 6; metastatic malignant melanoma, 1; metastatic carcinoid, 2; metastatic small cell carcinoma, 1; and metastatic lobular carcinoma of the breast, 1) were negative for OCT4, except for some cases of clear cell adenocarcinoma of the ovary. Four of 14 clear cell adenocarcinomas showed focal positive nuclear immunoreactivity for OCT4. OCT4 is a sensitive and relatively specific biomarker for the detection of dysgerminoma. It may also be useful in the diagnosis of gonadoblastoma, which contains similar cells and may be associated with dysgerminoma. OCT4 may aid in the detection of small foci of metastatic dygerminoma in extraovarian sites and may also help distinguish dysgerminoma from other primary and metastatic tumors of the ovary.Keywords
This publication has 24 references indexed in Scilit:
- Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2Laboratory Investigation, 2004
- Loss of 14-3-3σ in Prostate Cancer and Its PrecursorsClinical Cancer Research, 2004
- p53 Alteration in regional lymph node metastases from prostate carcinomaCancer, 1999
- p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapyCancer, 1999
- Cisplatin-Based Chemotherapy in Dysgerminoma of the Ovary: Thirteen-Year Experience at the Institut Gustave RoussyGynecologic Oncology, 1995
- In situ hybridization localizes the human OTF3 to chromosome 6p21.3→p22 and OTF3L to 12p13Cytogenetic and Genome Research, 1993
- Dysgerminoma. The Radiumhemmet series 1927-1984Cancer, 1990
- Placental alkaline phosphatase immunohistochemistry of intratubular malignant germ cells and associated testicular germ cell tumorsHuman Pathology, 1988
- Ovarian dysgerminoma: Report of seven cases and review of the literatureAmerican Journal of Obstetrics and Gynecology, 1988
- Natural history of dysgerminomaAmerican Journal of Obstetrics and Gynecology, 1982